Quantitative Concept
ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition
ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing
RYBREVANT: A Breakthrough in Lung Cancer Treatment
RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)
Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome
Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge
Brandon Capital Raises $180M Fund to Boost Australia and New Zealand Biotechs
Brandon Capital, biotechs, Australia, New Zealand, life sciences, venture capital, fund, startups, scale-ups
LGBTQ+ Populations Face Higher Cancer Risk Due to Barriers to Healthcare
LGBTQ+, cancer risk, barriers to healthcare, American Cancer Society, discrimination, minority stress
BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati
Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA
Gilead’s Trodelvy Fails to Meet Primary Endpoint in Confirmatory Trial for Urothelial Cancer
Gilead Sciences, Trodelvy, urothelial cancer, TROPiCS-04 study, overall survival, antibody-drug conjugate, oncology, clinical trials, FDA approval
Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration
Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy
NS Pharma’s Duchenne Muscular Dystrophy Therapy Viltepso Fails Confirmatory Trial
NS Pharma, Viltepso, Duchenne Muscular Dystrophy, Confirmatory Trial, Phase III, RACER53 Study, FDA Approval
NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment
Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment